Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESERVE-HF trial (Empagliflozin in underweight HFpEF patients)
jRCT1031250547Recruiting
- Sponsor
- Grant-in-Aid for Scientific Research (KAKENHI), Gunma Foundation for Medical and Health science
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of empagliflozin in heart failure with preserved ejection fraction (HFpEF), sponsored by Grant-in-Aid for Scientific Research (KAKENHI), Gunma Foundation for Medical and Health science. Primary endpoint: Change in skeletal muscle mass index from baseline to 4 months. Started Dec 2025; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on jRCT1031250547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250547.